GRPR and neoplasm: Due to the agonist characteristics, potentially longer tumor retention, and negligible pancreatic uptake of [68Ga]Ga-TacBOMB2 and [68Ga]Ga-TacBOMB3, [Thz14]Bombesin(7–14) is a promising vector for the design of GRPR-targeting radiopharmaceuticals, particularly for radioligand therapy applications to minimize toxicity to the pancreas.